SI2608796T1 - Inhibicija proteinske fukozilacije in vivo z uporabo fukoznih analogov - Google Patents

Inhibicija proteinske fukozilacije in vivo z uporabo fukoznih analogov

Info

Publication number
SI2608796T1
SI2608796T1 SI201131673T SI201131673T SI2608796T1 SI 2608796 T1 SI2608796 T1 SI 2608796T1 SI 201131673 T SI201131673 T SI 201131673T SI 201131673 T SI201131673 T SI 201131673T SI 2608796 T1 SI2608796 T1 SI 2608796T1
Authority
SI
Slovenia
Prior art keywords
vivo
inhibition
protein fucosylation
fucose analogs
fucose
Prior art date
Application number
SI201131673T
Other languages
English (en)
Slovenian (sl)
Inventor
Peter Senter
Stephen Alley
Dennis Benjamin
Original Assignee
Seattle Genetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics, Inc. filed Critical Seattle Genetics, Inc.
Publication of SI2608796T1 publication Critical patent/SI2608796T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SI201131673T 2010-08-05 2011-08-05 Inhibicija proteinske fukozilacije in vivo z uporabo fukoznih analogov SI2608796T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37111610P 2010-08-05 2010-08-05
PCT/US2011/046857 WO2012019165A2 (en) 2010-08-05 2011-08-05 Methods of inhibition of protein fucosylation in vivo using fucose analogs
EP11815404.6A EP2608796B1 (en) 2010-08-05 2011-08-05 Inhibition of protein fucosylation in vivo using fucose analogs

Publications (1)

Publication Number Publication Date
SI2608796T1 true SI2608796T1 (sl) 2019-03-29

Family

ID=45560106

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201131673T SI2608796T1 (sl) 2010-08-05 2011-08-05 Inhibicija proteinske fukozilacije in vivo z uporabo fukoznih analogov

Country Status (21)

Country Link
US (4) US9504702B2 (enExample)
EP (2) EP3513794A3 (enExample)
JP (4) JP5918235B2 (enExample)
KR (2) KR101950520B1 (enExample)
CN (2) CN103402525B (enExample)
AU (3) AU2011285490B2 (enExample)
CA (1) CA2803388C (enExample)
CY (1) CY1121419T1 (enExample)
DK (1) DK2608796T3 (enExample)
ES (1) ES2711622T3 (enExample)
HU (1) HUE043370T2 (enExample)
IL (2) IL224487A (enExample)
MX (1) MX356671B (enExample)
NZ (1) NZ606250A (enExample)
PL (1) PL2608796T3 (enExample)
PT (1) PT2608796T (enExample)
RU (2) RU2625768C2 (enExample)
SI (1) SI2608796T1 (enExample)
TR (1) TR201902439T4 (enExample)
WO (1) WO2012019165A2 (enExample)
ZA (1) ZA201300653B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2458541T5 (en) 2008-05-02 2025-08-04 Seagen Inc Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
EP3513794A3 (en) 2010-08-05 2019-10-16 Seattle Genetics, Inc. Fucose analogs for inhibition of protein fucosylation in vivo
CA2882725C (en) 2012-08-23 2021-03-09 Regents Of The University Of Minnesota Treatment of sickle cell disease and inflammatory conditions
US9328134B2 (en) 2013-02-22 2016-05-03 Amgen Inc. Carbohydrate phosphonate derivatives as modulators of glycosylation
CN106699886A (zh) * 2015-07-13 2017-05-24 西藏海思科药业集团股份有限公司 抗体依赖性细胞介导的细胞毒性(adcc)增强的奥法木抗体
MX385283B (es) * 2015-12-04 2025-03-18 Seagen Inc Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control.
JP6882339B2 (ja) * 2016-05-10 2021-06-02 アレス トレーディング ソシエテ アノニム ペルアセチルガラクトースを使った組換えタンパク質のタンパク質ガラクトシル化プロファイルを改変する方法
JP2018002666A (ja) * 2016-07-04 2018-01-11 国立研究開発法人理化学研究所 フコース類似体と糖を検出する方法
BR112019025775A2 (pt) * 2017-06-07 2020-06-23 Seattle Genetics, Inc. Células t com fucosilação de superfície reduzida e métodos para fazer e usar as mesmas
MX2020005662A (es) 2017-12-01 2020-08-20 Pfizer Anticuerpos anti-cxcr5 y composiciones y usos de los mismos.
MY206031A (en) 2018-03-29 2024-11-26 Pfizer Lfa3 variants and compositions and uses thereof
CN112638944A (zh) 2018-08-23 2021-04-09 西进公司 抗tigit抗体
CN113226330B (zh) * 2018-12-27 2024-09-20 学校法人庆应义塾 抗人诺如病毒剂
US20230022796A1 (en) * 2019-12-19 2023-01-26 Merck Patent Gmbh Methods and compositions for modulating the glycosylation profile of proteins
TWI877278B (zh) * 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
IL272389A (en) 2020-01-30 2021-08-31 Yeda Res & Dev Kits containing antibodies to PD-L1 and their uses in therapy
CN116194089A (zh) * 2020-06-03 2023-05-30 西蒙弗雷泽大学 蛋白质岩藻糖基化抑制剂及其用途
TW202300178A (zh) 2021-03-18 2023-01-01 美商西根公司 內化的生物活性化合物偶聯物選擇性釋放藥物
EP4352094A1 (en) 2021-06-07 2024-04-17 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
CN113413465B (zh) * 2021-06-15 2022-06-03 北京大学 岩藻糖基化抑制剂在抗癌导致炎症中的应用
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs
WO2024191807A1 (en) 2023-03-10 2024-09-19 Seagen Inc. Methods of treating cancer with anti-tigit antibodies
WO2025262564A1 (en) 2024-06-17 2025-12-26 Pfizer Inc. Use of anti-cxcr5 antibodies

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440780A (en) 1979-06-01 1984-04-03 Chevron Research Company Fungicidal 3-(N-acyl-N-arylamino)-and 3-(N-thionoacyl-N-arylamino)-gamma-butyrolactones and gamma-thiobutyrolactones
JPH0660189B2 (ja) 1986-01-22 1994-08-10 財団法人微生物化学研究会 ２，６−ジデオキシ−２−フルオロ−ｌ−タロピラノ−ス又はその誘導体とその製造法
FR2630914A1 (fr) 1988-05-04 1989-11-10 Hoechst Sa Laboratoires Nouveaux analogues du l-fucose, leur procede de preparation, application de ces analogues a la preparation de nouveaux glycals, anthracyclines obtenues a l'aide de ces glycals et utilisation desdites anthracyclines en tant que medicaments
KR100211417B1 (ko) 1990-11-30 1999-10-01 유충식 L-탈로피라노시드 유도체 및 그의 제조방법
US5461143A (en) 1991-03-18 1995-10-24 The Scripps Research Institute Oligosaccharide enzyme substrates and inhibitors: methods and compositions
US5210078A (en) * 1991-04-30 1993-05-11 The Biomembrane Institute Trifluoromethyl analogs of fucose and uses thereof
CA2121365C (en) 1991-10-15 2000-11-28 Chi-Huey Wong Production of fucosylated carbohydrates by enzymatic fucosylation synthesis of sugar nucleotides; and in situ regeneration of gdp-fucose
DE69425439D1 (de) 1993-09-29 2000-09-07 Nissin Food Products Ltd In stellung 21 substituierte steroide
US5481143A (en) 1993-11-15 1996-01-02 Burdick; Brian K. Self starting brushless d.c. motor
FR2723947B1 (fr) 1994-08-31 1996-09-27 Adir Nouveaux composes tetrahydropyraniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19524515A1 (de) 1995-07-05 1997-01-09 Deutsches Krebsforsch Saccharid-Konjugate
US6713287B1 (en) 1995-10-24 2004-03-30 The Scripps Research Institute Enzymatic synthesis of L-fucose and L-fucose analogs
WO1998018805A2 (en) 1996-10-28 1998-05-07 Novartis Ag Sugar derivatives as sialyl lewis x mimetics
US5770407A (en) 1996-12-10 1998-06-23 The Scripps Research Institute Process for preparing nucleotide inhibitors of glycosyltransferases
JP4451933B2 (ja) 1996-12-27 2010-04-14 住友化学株式会社 遺伝子操作による植物へのｐｐｏ阻害性除草剤耐性付与法
US6075134A (en) 1997-05-15 2000-06-13 The Regents Of The University Of California Glycoconjugates and methods
JPH1135593A (ja) 1997-07-18 1999-02-09 Daikin Ind Ltd ２−フルオロフコシル−ｎ−アロイルグルコサミン誘導体及びその中間物、並びにそれらの製造方法
US6670330B1 (en) 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
JPWO2003085118A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
EP1587519A4 (en) 2003-01-10 2006-05-31 Threshold Pharmaceuticals Inc Treatment of cancer with 2-deoxyglucose
WO2004091499A2 (en) 2003-04-09 2004-10-28 Neose Technologies, Inc. Intracellular formation of peptide conjugates
SG155777A1 (en) 2003-04-09 2009-10-29 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods
US7332334B2 (en) 2003-04-18 2008-02-19 Oklahoma Medical Research Foundation Hematopoietic stem cells treated by in vitro fucosylation and methods of use
JPWO2005017155A1 (ja) 2003-06-18 2006-10-12 中外製薬株式会社 フコーストランスポーター
AU2004280066A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Genomically modified cell
RU2006126718A (ru) 2003-12-23 2008-01-27 Проджен Индастриз Лимитед (Au) Миметики гликозаминогликанов (gag)
DE102004032421A1 (de) 2004-07-05 2006-01-26 Bayer Cropscience Ag Phenylsubstituierte [1.2]-Oxazin-3,5-dion-und Dihydropyron-Derivate
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
EP1829961A4 (en) 2004-12-22 2008-06-04 Chugai Pharmaceutical Co Ltd PROCESS FOR PREPARING ANTIBODY USING A CELL WHOSE FUCOSE CARRIER FUNCTION IS INHIBITED
AU2006236225C1 (en) 2005-04-19 2013-05-02 Seagen Inc. Humanized anti-CD70 binding agents and uses thereof
WO2007048122A2 (en) 2005-10-21 2007-04-26 Genzyme Corporation Antibody-based therapeutics with enhanced adcc activity
WO2007064448A2 (en) 2005-11-28 2007-06-07 Ramot At Tel Aviv University, Ltd. Cancer treatment using fts and 2-deoxyglucose
US7956162B2 (en) * 2005-12-21 2011-06-07 Viventia Biotechnologies Inc. Cancer-associated antigen
WO2007081031A1 (ja) 2006-01-16 2007-07-19 Hokkaido University 糖転移酵素阻害剤
US20070249014A1 (en) 2006-02-10 2007-10-25 Invitrogen Corporation Labeling and detection of post translationally modified proteins
MX2008010833A (es) 2006-02-24 2008-11-12 Univ Texas Compuestos de hexosa para tratar cancer.
CA2642189A1 (en) 2006-02-24 2007-09-07 University Of Miami Mannose derivatives for killing tumor cells
JP5885378B2 (ja) 2006-03-22 2016-03-22 ザ スクリプス リサーチ インスティテュート グリコペプチドの調製法
US9149489B2 (en) 2006-04-27 2015-10-06 Board Of Regents, University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
WO2009108926A1 (en) 2008-02-29 2009-09-03 Board Of Regents, The University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
CN101646688A (zh) 2006-10-24 2010-02-10 特鲁比昂药品公司 利用栗精胺提高抗体依赖性细胞毒性的方法
EP2457573A1 (en) 2007-02-09 2012-05-30 GlycoMimetics, Inc. Methods of use of glycomimetics with replacements for hexoses and N-Acetyl hexosamines
WO2008131024A1 (en) 2007-04-17 2008-10-30 Board Of Regents, The University Of Texas System Iodo-hexose compounds useful to treat cancer
CN101062939A (zh) 2007-05-17 2007-10-31 北京热景生物技术有限公司 检测肝癌岩藻糖基化高尔基蛋白gp73的装置及试剂盒
WO2009052431A2 (en) 2007-10-19 2009-04-23 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
WO2009114641A1 (en) 2008-03-11 2009-09-17 Genentech, Inc. Antibodies with enhanced adcc function
ES2458541T5 (en) 2008-05-02 2025-08-04 Seagen Inc Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2009143078A2 (en) 2008-05-19 2009-11-26 Board Of Regents, The University Of Texas System Methods of treating brain cancer using hexose compounds
WO2009143515A2 (en) 2008-05-23 2009-11-26 University Of Miami Treatment using continuous low dose application of sugar analogs
CA2728344A1 (en) * 2008-06-16 2010-01-14 Academia Sinica Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment
WO2010111713A2 (en) 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. N-linked glycan biosynthesis modulators
WO2011137528A1 (en) 2010-05-06 2011-11-10 Simon Fraser University Methods and compounds for inhibiting glycosyltransferases
US20110288880A1 (en) 2010-05-07 2011-11-24 Patient Care Automation Services, Inc. Targeted health care messaging
EP3513794A3 (en) 2010-08-05 2019-10-16 Seattle Genetics, Inc. Fucose analogs for inhibition of protein fucosylation in vivo
CA2824175A1 (en) 2011-01-11 2012-07-19 The University Of Texas M.D. Anderson Cancer Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases
US8979675B2 (en) 2012-04-25 2015-03-17 Nike, Inc. Golf ball core having radial appendages
CA2882725C (en) 2012-08-23 2021-03-09 Regents Of The University Of Minnesota Treatment of sickle cell disease and inflammatory conditions
MX385283B (es) 2015-12-04 2025-03-18 Seagen Inc Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control.

Also Published As

Publication number Publication date
AU2017279653A1 (en) 2018-01-18
US20130129784A1 (en) 2013-05-23
ZA201300653B (en) 2014-03-26
RU2013109415A (ru) 2014-09-10
PL2608796T3 (pl) 2019-04-30
JP2020040974A (ja) 2020-03-19
EP2608796A4 (en) 2014-06-11
JP5918235B2 (ja) 2016-05-18
EP2608796A2 (en) 2013-07-03
CY1121419T1 (el) 2020-05-29
US20210260086A1 (en) 2021-08-26
JP2016175909A (ja) 2016-10-06
IL244019B (en) 2019-09-26
EP2608796B1 (en) 2018-11-21
AU2016204495A1 (en) 2016-07-21
US11033561B2 (en) 2021-06-15
AU2011285490B2 (en) 2016-04-21
JP6113887B2 (ja) 2017-04-12
WO2012019165A2 (en) 2012-02-09
AU2011285490A1 (en) 2013-01-10
RU2625768C2 (ru) 2017-07-18
IL244019A0 (en) 2016-04-21
MX2013001303A (es) 2014-07-24
IL224487A (en) 2016-07-31
ES2711622T3 (es) 2019-05-06
JP2013541503A (ja) 2013-11-14
CN103402525A (zh) 2013-11-20
US9504702B2 (en) 2016-11-29
US20170035790A1 (en) 2017-02-09
HUE043370T2 (hu) 2019-08-28
EP3513794A2 (en) 2019-07-24
JP6622238B2 (ja) 2019-12-18
CA2803388C (en) 2019-11-05
CN103402525B (zh) 2017-03-01
JP2017149723A (ja) 2017-08-31
RU2017122482A3 (enExample) 2019-01-30
US10342811B2 (en) 2019-07-09
WO2012019165A3 (en) 2013-08-15
EP3513794A3 (en) 2019-10-16
CN107007615A (zh) 2017-08-04
KR101950520B1 (ko) 2019-02-20
TR201902439T4 (tr) 2019-03-21
US20200061091A1 (en) 2020-02-27
PT2608796T (pt) 2019-02-25
RU2017122482A (ru) 2019-01-30
CA2803388A1 (en) 2012-02-09
DK2608796T3 (en) 2019-03-18
KR20130135240A (ko) 2013-12-10
NZ606250A (en) 2015-04-24
MX356671B (es) 2018-06-08
KR20190022884A (ko) 2019-03-06

Similar Documents

Publication Publication Date Title
IL244019B (en) Methods for inhibiting protein fucosylation in vivo using fucose analogs
GB2502236B (en) Indications of cross-section of small branched blood vessels
ZA201209561B (en) Compositions and methods related to protein a (spa) variants
ZA201308086B (en) Derivatives of 1-anino-2-cyclopropylboronic acid
EP2438185A4 (en) METHODS FOR MODULATING FUCOSYLATION OF GLYCOPROTEINS
GB2492924B (en) Ceramic footbath boots
GB201003274D0 (en) Methods of connecting
ZA201301601B (en) Treatment of diseases
GB201311895D0 (en) Extraction of gold
EP2563768A4 (en) MANUFACTURE OF FEBUXOSTAT
ZA201303416B (en) Methods for enhancing oxygenation of jeopardized tissue
IL225754A0 (en) Processes for the preparation of lubiprostone
EP2744441A4 (en) DENTAL IMPLANTS - CUSTOM PILLAR REPLICAS AND IMPLANT ANALOGS
SI2632443T1 (sl) Proizvodnja orodisperzibilnih filmov
EP2684869A4 (en) PREPARATION OF 3-MERCAPOTOPROPIONATES
EP2591368A4 (en) METHOD FOR DETERMINING ETHANOL CONSUMPTION
EP2548881A4 (en) PROCESS FOR THE PREPARATION OF DROSPIRENONE
EP2760876A4 (en) NEW PROCESS FOR SYNTHESIS OF FUCOSE
EP2536688A4 (en) STABLE DOSAGE FORMS OF LEVOMILNACIPRAN
EP2459540A4 (en) PREPARATION OF FIPAMEZOLE
EP2548554A4 (en) IN VIVO proteolysis INHIBITORS
ZA201308467B (en) N-acetyl beta alanine methods of use
TWM390131U (en) Improved structure of dental scaler
TWM390678U (en) Improvement of footwear body structure
TWM385961U (en) Structure of style brooches